snp cyp2b6 c 7817765 60  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    Thermo Fisher snp cyp2b6 c 7817765 60
    Nevirapine plasma concentrations following a 200 mg dose to A) African Americans and B) European Americans. The concentrations (mean ± SEM) are stratified by <t>CYP2B6</t> 516G > T genotype: circles GG, squares GT and triangles TT.
    Snp Cyp2b6 C 7817765 60, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 97/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/snp cyp2b6 c 7817765 60/product/Thermo Fisher
    Average 97 stars, based on 10 article reviews
    Price from $9.99 to $1999.99
    snp cyp2b6 c 7817765 60 - by Bioz Stars, 2020-08
    97/100 stars

    Images

    1) Product Images from "Measuring the Overall Genetic Component of Nevirapine Pharmacokinetics and the Role of Selected Polymorphisms: Towards Addressing the Missing Heritability in Pharmacogenetic Phenotypes?"

    Article Title: Measuring the Overall Genetic Component of Nevirapine Pharmacokinetics and the Role of Selected Polymorphisms: Towards Addressing the Missing Heritability in Pharmacogenetic Phenotypes?

    Journal: Pharmacogenetics and genomics

    doi: 10.1097/FPC.0b013e32836533a5

    Nevirapine plasma concentrations following a 200 mg dose to A) African Americans and B) European Americans. The concentrations (mean ± SEM) are stratified by CYP2B6 516G > T genotype: circles GG, squares GT and triangles TT.
    Figure Legend Snippet: Nevirapine plasma concentrations following a 200 mg dose to A) African Americans and B) European Americans. The concentrations (mean ± SEM) are stratified by CYP2B6 516G > T genotype: circles GG, squares GT and triangles TT.

    Techniques Used:

    2) Product Images from "Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes"

    Article Title: Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0086919

    Goodness of Fit. Individual predicted EFV concentrations (IPRED) versus observed concentrations, by CYP2B6*6 genotype (B66).
    Figure Legend Snippet: Goodness of Fit. Individual predicted EFV concentrations (IPRED) versus observed concentrations, by CYP2B6*6 genotype (B66).

    Techniques Used:

    Distribution of estimated patient AUC values by CYP2B6 genotype. CYP2B6*1/*1, CYP2B6 *1/*6, and CYP2B6 *6/*6. Dotted line = the mean AUC value in the product label.
    Figure Legend Snippet: Distribution of estimated patient AUC values by CYP2B6 genotype. CYP2B6*1/*1, CYP2B6 *1/*6, and CYP2B6 *6/*6. Dotted line = the mean AUC value in the product label.

    Techniques Used:

    3) Product Images from "Pharmacogenetics of artemether‐lumefantrine influence on nevirapine disposition: Clinically significant drug–drug interaction?) Pharmacogenetics of artemether‐lumefantrine influence on nevirapine disposition: Clinically significant drug–drug interaction?"

    Article Title: Pharmacogenetics of artemether‐lumefantrine influence on nevirapine disposition: Clinically significant drug–drug interaction?) Pharmacogenetics of artemether‐lumefantrine influence on nevirapine disposition: Clinically significant drug–drug interaction?

    Journal: British Journal of Clinical Pharmacology

    doi: 10.1111/bcp.13821

    Scatter plots showing significant differences in plasma nevirapine concentrations between patients based on CYP2B6 c.516G > T genotypes (A), CYP2B6 c.785A > G genotypes (B), CYP2B6 c.983T > C genotypes (C) and gender (D)
    Figure Legend Snippet: Scatter plots showing significant differences in plasma nevirapine concentrations between patients based on CYP2B6 c.516G > T genotypes (A), CYP2B6 c.785A > G genotypes (B), CYP2B6 c.983T > C genotypes (C) and gender (D)

    Techniques Used:

    4) Product Images from "A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study"

    Article Title: A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study

    Journal: Pharmacogenomics and Personalized Medicine

    doi: 10.2147/PGPM.S86446

    Study flow diagram. Abbreviations: ART, antiretroviral therapy; CYP2B6 , cytochrome P450 2B6 .
    Figure Legend Snippet: Study flow diagram. Abbreviations: ART, antiretroviral therapy; CYP2B6 , cytochrome P450 2B6 .

    Techniques Used: Flow Cytometry

    Efavirenz concentrations in plasma at 4, 12, and 24 weeks. Note: The boxes represent interquartile range and lines represent minimum and maximum value. Abbreviation: CYP2B6 , cytochrome P450 2B6 .
    Figure Legend Snippet: Efavirenz concentrations in plasma at 4, 12, and 24 weeks. Note: The boxes represent interquartile range and lines represent minimum and maximum value. Abbreviation: CYP2B6 , cytochrome P450 2B6 .

    Techniques Used:

    5) Product Images from "Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study"

    Article Title: Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study

    Journal: BMC Infectious Diseases

    doi: 10.1186/1471-2334-13-261

    Kaplan–Meier curves indicating cumulative hazard for the development of efavirenz-based highly active antiretroviral therapy associated neuropsychiatric symptoms between the different CYP2B6 genotype groups during 12 weeks in Ugandan HIV patients.
    Figure Legend Snippet: Kaplan–Meier curves indicating cumulative hazard for the development of efavirenz-based highly active antiretroviral therapy associated neuropsychiatric symptoms between the different CYP2B6 genotype groups during 12 weeks in Ugandan HIV patients.

    Techniques Used:

    6) Product Images from "Cytochrome P450 2B6 genetic variants are associated with plasma nevirapine levels and clinical response in HIV-1 infected Kenyan women: a prospective cohort study"

    Article Title: Cytochrome P450 2B6 genetic variants are associated with plasma nevirapine levels and clinical response in HIV-1 infected Kenyan women: a prospective cohort study

    Journal: AIDS Research and Therapy

    doi: 10.1186/s12981-015-0052-0

    Differences in log 10 -transformed plasma nevirapine levels by genotype. Panel A, Log 10 -transformed plasma nevirapine levels for each CYP2B6 516G > T genotype: GG, GT, and TT. Panel B, Log 10 -transformed plasma nevirapine levels for each CYP2B6 983T > C genotype: TC and TT. Panel C, Log 10 -transformed plasma nevirapine levels for each CYP2B6 phenotype (predicted from CYP2B6 516G > T and 983T > C genotypes). EM = extensive metabolizer, IM = intermediate metabolizer, SM = slow metabolizer.
    Figure Legend Snippet: Differences in log 10 -transformed plasma nevirapine levels by genotype. Panel A, Log 10 -transformed plasma nevirapine levels for each CYP2B6 516G > T genotype: GG, GT, and TT. Panel B, Log 10 -transformed plasma nevirapine levels for each CYP2B6 983T > C genotype: TC and TT. Panel C, Log 10 -transformed plasma nevirapine levels for each CYP2B6 phenotype (predicted from CYP2B6 516G > T and 983T > C genotypes). EM = extensive metabolizer, IM = intermediate metabolizer, SM = slow metabolizer.

    Techniques Used: Transformation Assay

    7) Product Images from "Relationships between CYP2B6 Polymorphisms and Pharmacokinetics Following a Single Dose of Nevirapine or Efavirenz in African Americans"

    Article Title: Relationships between CYP2B6 Polymorphisms and Pharmacokinetics Following a Single Dose of Nevirapine or Efavirenz in African Americans

    Journal: The Journal of infectious diseases

    doi: 10.1086/597125

    Linkage disequilibrium (LD) plot of CYP2B6 polymorphisms. Data from all 34 participants are included. Black, r 2 = 1; shades of grey 0
    Figure Legend Snippet: Linkage disequilibrium (LD) plot of CYP2B6 polymorphisms. Data from all 34 participants are included. Black, r 2 = 1; shades of grey 0

    Techniques Used:

    Plasma concentration-time curves for nevirapine and efavirenz. Each curve represents a different study participant. A pre-dose concentration of zero was assigned to all participants. Individuals with a composite CYP2B6 516/983 slow metabolizer genotype
    Figure Legend Snippet: Plasma concentration-time curves for nevirapine and efavirenz. Each curve represents a different study participant. A pre-dose concentration of zero was assigned to all participants. Individuals with a composite CYP2B6 516/983 slow metabolizer genotype

    Techniques Used: Concentration Assay

    8) Product Images from "The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children) The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children"

    Article Title: The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children) The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children

    Journal: British Journal of Clinical Pharmacology

    doi: 10.1111/bcp.12934

    Simulated mid‐dose concentrations across weight‐bands (left) and by different 516GT|983TC genotypes (right) based on suggested most optimal dosing. Red horizontal lines correspond to efavirenz concentrations of 1 mg l −1 and 4 mg l −1 3 . Breaks in the percentile plot correspond to 25th, median and 75th percentile and whiskers correspond to 5th and 95th percentile of the simulated data. CYP2B6 ( ) 516GG|983TT; ( ) 516GG|983TC; ( ) 516GG|983CC; ( ) 516GT|983TT; ( ) 516GT|983TC; ( ) 516TT|983TT
    Figure Legend Snippet: Simulated mid‐dose concentrations across weight‐bands (left) and by different 516GT|983TC genotypes (right) based on suggested most optimal dosing. Red horizontal lines correspond to efavirenz concentrations of 1 mg l −1 and 4 mg l −1 3 . Breaks in the percentile plot correspond to 25th, median and 75th percentile and whiskers correspond to 5th and 95th percentile of the simulated data. CYP2B6 ( ) 516GG|983TT; ( ) 516GG|983TC; ( ) 516GG|983CC; ( ) 516GT|983TT; ( ) 516GT|983TC; ( ) 516TT|983TT

    Techniques Used:

    Simulated mid‐dose concentrations across weight‐bands (left) and by different 516GT|983TC genotypes (right) based on dose recommendations tested in IMPACT study P1070 applied to our population. Red horizontal lines correspond to efavirenz concentrations of 1 mg l −1 and 4 mg l −1 3 . Breaks in the percentile plot correspond to 25th, median and 75th percentile and whiskers correspond to 5th and 95th percentile of the simulated data. CYP2B6 ( ) 516GG|983TT; ( ) 516GG|983TC; ( ) 516GG|983CC; ( ) 516GT|983TT; ( ) 516GT|983TC; ( ) 516TT|983TT
    Figure Legend Snippet: Simulated mid‐dose concentrations across weight‐bands (left) and by different 516GT|983TC genotypes (right) based on dose recommendations tested in IMPACT study P1070 applied to our population. Red horizontal lines correspond to efavirenz concentrations of 1 mg l −1 and 4 mg l −1 3 . Breaks in the percentile plot correspond to 25th, median and 75th percentile and whiskers correspond to 5th and 95th percentile of the simulated data. CYP2B6 ( ) 516GG|983TT; ( ) 516GG|983TC; ( ) 516GG|983CC; ( ) 516GT|983TT; ( ) 516GT|983TC; ( ) 516TT|983TT

    Techniques Used:

    Individual mid‐dose concentrations estimated by the population pharmacokinetic model (black dots) plotted on top of the mid‐dose concentrations (percentile plots) simulated across weight‐bands (left) and by different CYP2B6 516GT|983TC subgroups (right). Red horizontal lines correspond to efavirenz concentrations of 1 mg l −1 and 4 mg l −1 3 . Breaks in the percentile plot correspond to 25th, median and 75th percentile and whiskers correspond to 5th and 95th percentile of the simulated data. CYP2B6 ( ) 516GG|983TT; ( ) 516GG|983TC; ( ) 516GG|983CC; ( ) 516GT|983TT; ( ) 516GT|983TC; ( ) 516TT|983TT
    Figure Legend Snippet: Individual mid‐dose concentrations estimated by the population pharmacokinetic model (black dots) plotted on top of the mid‐dose concentrations (percentile plots) simulated across weight‐bands (left) and by different CYP2B6 516GT|983TC subgroups (right). Red horizontal lines correspond to efavirenz concentrations of 1 mg l −1 and 4 mg l −1 3 . Breaks in the percentile plot correspond to 25th, median and 75th percentile and whiskers correspond to 5th and 95th percentile of the simulated data. CYP2B6 ( ) 516GG|983TT; ( ) 516GG|983TC; ( ) 516GG|983CC; ( ) 516GT|983TT; ( ) 516GT|983TC; ( ) 516TT|983TT

    Techniques Used:

    9) Product Images from "Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults"

    Article Title: Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults

    Journal: British Journal of Clinical Pharmacology

    doi: 10.1111/j.1365-2125.2012.04288.x

    Impact of CYP2B6 polymorphisms; 516G > T (A), 785A > G (B), 18492T > C (C) and 21563C > T (1D) on efavirenz (EFV) plasma concentrations. Middle bar indicates the median and grey bar indicates the interquartile range. Mann–Whitney tests were used to compare efavirenz concentrations between two genotypes
    Figure Legend Snippet: Impact of CYP2B6 polymorphisms; 516G > T (A), 785A > G (B), 18492T > C (C) and 21563C > T (1D) on efavirenz (EFV) plasma concentrations. Middle bar indicates the median and grey bar indicates the interquartile range. Mann–Whitney tests were used to compare efavirenz concentrations between two genotypes

    Techniques Used: MANN-WHITNEY

    Linkage disequilibrium of CYP2B6 for each polymorphism, data represents six SNPs in Haploview 4.2 software. Red quadrate without D' worth display mean D' = 1, LOD ≥2 while pale blue square mean D' = 1, LOD
    Figure Legend Snippet: Linkage disequilibrium of CYP2B6 for each polymorphism, data represents six SNPs in Haploview 4.2 software. Red quadrate without D' worth display mean D' = 1, LOD ≥2 while pale blue square mean D' = 1, LOD

    Techniques Used: Software

    CYP2B6 GAC haplotype. Middle bar indicates the median and grey box indicates the interquartile range. Asterisks represent an individual subject
    Figure Legend Snippet: CYP2B6 GAC haplotype. Middle bar indicates the median and grey box indicates the interquartile range. Asterisks represent an individual subject

    Techniques Used:

    10) Product Images from "Tell-Tale SNPs: The Role of CYP2B6 in Methadone Fatalities"

    Article Title: Tell-Tale SNPs: The Role of CYP2B6 in Methadone Fatalities

    Journal: Journal of Analytical Toxicology

    doi: 10.1093/jat/bkw135

    Comparison for various CYP2B6 SNPs with SEM of (A) mean blood methadone concentrations and (B) mean [Methadone]/[EDDP] ratios. * Statistically significant difference, P
    Figure Legend Snippet: Comparison for various CYP2B6 SNPs with SEM of (A) mean blood methadone concentrations and (B) mean [Methadone]/[EDDP] ratios. * Statistically significant difference, P

    Techniques Used:

    Related Articles

    other:

    Article Title:
    Article Snippet: TaqMan™ assays were used to genotype CYP2B6 polymorphisms 516G > T (rs3745274, assay ID C_7817765_60) and 983T > C (rs28399499, assay ID C_60732328_10).

    Article Title:
    Article Snippet: Predesigned TaqMan assays (Applied Biosystems, Foster City, CA, USA) were used to genotype the predesigned TaqMan assays (Applied Biosystems) and were also used to genotype the CYP2B6 c.516G > T (assay ID C__7817765_60), c.64C > T (assay ID C__2818162_20), c.499C > G (assay ID C__2752377_10), c.1375A > G (assay ID C__2741754_10), c.1459C > T (assay ID C__30634242_40), g.3003T > C (assay ID C__2818167_10), and g.21563C > T (assay ID C__22275631_10).

    Article Title:
    Article Snippet: CYP2B6 516 G > T (rs3745274), UGT1A9 i399C > T (rs2741049), and 766 G > A (rs58597806) SNPs were identified by validated TaqMan SNP Genotyping Assays (assay ID: C_7817765_60, C_34816143_20, and C_9096281_10, respectively) (Life Technologies, Carlsbad, California, USA) using an ABI 7500 Real-Time PCR system (Life Technologies) and TaqMan®Universal Master Mix II with UNG (Life Technologies) according to the manufacturer’s instruction.

    Article Title:
    Article Snippet: Allelic discrimination reactions were performed using TaqMan® (Applied Biosystems, CA, USA) genotyping assays: (C___7586657_20 for ABCB1 3435C > T, C___7817765_60, for ABCB1 rs3842T > C, C__29560333_20, for CYP2B6 516G > T [CYP2B6*6 ], for CYP2B6 136A > G [CYP2B6*11 ], C__26201809_30 for CYP3A5 6986A > G [CYP3A5*3 ], C__30203950_10 for CYP3A5 14690G > A [CYP3A5*6 ]) and C__32287188_10 for CYP3A5 g.27131_27132insT [CYP3A5*7 ] on ABI 7500 FAST (Applied Biosystems, Foster City, CA).

    Article Title:
    Article Snippet: In brief genotyping was performed using TaqMan drug metabolism genotyping assay reagents for allelic discrimination (Applied Biosystems Genotyping Assays) with the following ID numbers for each SNP: C__7817765_60 for CYP2B6*6 (c.516G4T, rs3745274), C__60732328_20 for CYP2B6*18 (c.983T4C, rs28399499), C__26201809_30 for CYP3A5*3 (c.6986A4G, rs776746), C__30203950_10 for CYP3A5*6 (g.14690G4A,rs10264272) and C__32287188_10 for CYP3A5*7 (g.27131_27132 insT rs41303343) and C__11711730_20) for ABCB1 c.4036A >G (rs3842), and C__11711730_20 for CYP3A4*1B ( −392A >G, rs2740574).

    Article Title:
    Article Snippet: Taqman Genotyping Master mix and assays CYP2B6 516G > T (rs3745274, catalogue number C___7817765_60), CYP2B6 983T > C (rs28399499, catalogue number C__60732328_20), CYP2B6 15582C > T (rs4803419, catalogue number C___7817764_10), CYP2A6 -48A > C (rs28399433, catalogue number C__30634332_10) CYP2A6*9B 1836G > T (rs8192726, catalogue number C__29560333_20) NR1I2 63396C > T (rs2472677, catalogue number C_2607845), NR1I3 540C > T (rs2307424, catalogue number C__25746794_20) and NR1I3 1089T > C (rs3003596, catalogue number C__16194070_10) were purchased from Life Technologies (Paisley, Renfrewshire, UK).

    Article Title:
    Article Snippet: Genotyping was performed using TaqMan® drug metabolism genotyping assay reagents (Applied Biosystems Genotyping Assays) for allelic discrimination as described previously , with the following ID numbers for each SNP: C_7817765_60 for CYP2B6*6 (rs3745274), C_26201809_30 for CYP3A5*3 (rs776746), C_30203950_10 for CYP3A5*6 (rs10264272), C_25625805_10 for CYP2C9*2 (rs1799853), C_27104892_10 for CYP2C9*3 (rs1057910), C_25986767_70 for CYP2C19*2 (rs4244285), C_27861809_10 for CYP2C19*3 (rs4986893), C_9581699_80 for CYP2J2*7 (rs890293), C_8890131_30 for POR*28 (rs1057868), and C_11711730_20 for ABCB1 (rs3842).

    Article Title:
    Article Snippet: The PCR protocol involved an initial denaturation step at 95°C for 15 min, followed by 50 cycles of amplification at 95°C for 15 s and final annealing at 60°C for 1 min. TaqMan® Genotyping Master Mix and assays for CYP2B6 516G > T (rs3745274; ID: C_7817765_60), CYP2B6 983T > C (rs28399499; ID: C_60732328_20), CYP2B6 15582C > T (rs4803419; ID: C_7817764_10), CYP3A4 *22 (rs35599367, C__59013445_10), CYP3A5 6986G > A (rs776746, C__59013445_10), NR1I3 (rs3003596, C__16194070_10 and rs2307424, C__25746794_20), NR1I2 63396C > T (rs2472677, C__26079845_10), and ABCC10 (rs2125739, C__16173668_10) were obtained from Life Technologies Ltd (Paisley, UK).

    Article Title:
    Article Snippet: In brief genotyping was performed using TaqMan® drug metabolism genotyping assay reagents for allelic discrimination (Applied Biosystems Genotyping Assays) with the following ID numbers for each SNP: C__7817765_60 for CYP2B6∗ 6 (c.516G4T, rs3745274), C__26201809_30 for CYP3A5∗ 3 (c.6986A4G, rs776746), C__25625805_10 for CYP2C9∗ 2 (rs1799853), C__27104892_10 for CYP2C9∗ 3 (rs1057910), C__25986767_70 for CYP2C19∗ 2 (rs4244285), C__27861809_10 for CYP2C19∗ 3 (rs4986893), C_9581699_80 for CYP2J2∗ 7 (rs890293), C_8890131_30 for POR∗ 28 (rs1057868), and C__11711730_20 for ABCB1 (rs3842).

    Article Title:
    Article Snippet: CYP2B6 genotyping Predesigned TaqMan assays (Thermo Fisher Scientific, Waltham, MA, USA) were used to genotype the CYP2B6 c.516G > T (assay ID C_7817765_60), c.64C > T (assay ID C_2818162_20), c.499C > G (assay ID C_2752377_10), c.1375A > G (assay ID C_2741754_10), c.1459C > T (assay ID C_30634242_40), g.3003T > C (assay ID C_2818167_10), and g.21563C > T (assay ID C_22275631_10).

    Article Title:
    Article Snippet: The assays used to genotype CYP2B6 516G > T (rs3745274), ABCB1 3435C > T (rs1045642) and CYP3A5 6986A > G (rs776746) were Applied Biosystems C_7817765_60, C_7586657_1, and C_26201809_30, respectively.

    Article Title:
    Article Snippet: Pre-designed TaqMan assays (Applied Biosystems, Foster City, CA) were used to genotype the CYP2B6 g.3003T > C (assay ID C__2818167_10), c.516G > T (assay ID C__7817765_60), g.18492C > T (assay ID C__26823975_10), g.21563C > T (assay ID C__22275631_10), c.64C > T (assay ID C__2818162_20), c.499C > G (assay ID C__2752377_10), c.1375A > G (assay ID C__2741754_10) and c.1459C > T (assay ID C__30634242_40).

    Article Title:
    Article Snippet: The following Life TechnologiesTM TaqMan SNP Genotyping kits were used to determine CYP2B6 genotypes: (i) C__26823974_30 (rs2279344), (ii) C__30634242_40 (rs3211371), (iii) C___7817765_60 (rs3745274), (iv) C___7817764_10 (rs4803419), (v) C___2818162_20 (rs8192709), (vi) C__22275631_10 (rs8192719), (vii) C__30634236_20 (rs12721655) and (viii) C__33845840_20 (rs35979566).

    Article Title:
    Article Snippet: All participants were genotyped for CYP2B6*6 and *11 , CYP3A5*3 ,*6 and *7 and ABCB1 (3435CT and rs3842).Allelic discrimination reactions were performed using TaqMan (Applied Biosystems, CA, USA) genotyping assays: (C___7586657_20 for ABCB1 3435C > T, C___7817765_60, for ABCB1 rs3842T > C, C__29560333_20, for CYPB6 516G > T [CYP2B6*6 ], for CYP2B6 136A > G [CYP2B6*11 ], C__26201809_30 for CYP3A5 6986A > G [CYP3A5*3 ], C_16194070_10 for NR1I3 rs3003596T/C, C_30634332_10 for CYP2A6 -48T>G [CYP2A6*9 ], C_34816076_20 for CYP2A6 5065 G>A [CYP2A6*17 ], C__30203950_10 for CYP3A5 14690G > A [CYP3A5*6 ]) and C__32287188_10 for CYP3A5 g.27131_27132insT [CYP3A5*7 ] on ABI 7500 FAST (Applied Biosystems, Foster City, CA).

    Article Title:
    Article Snippet: TaqMan assays were used to genotype CYP2B6 516G > T (rs3745274, Assay ID: C___7817765_60) and ABCB1 3435C > T (rs1045642, Assay ID: C___7586657_20).

    Article Title:
    Article Snippet: The PCR protocol involved an initial denaturation step at 95°C for 15 min, followed by 50 cycles of amplification at 95°C for 15 s and final annealing at 60°C for 1 min. TaqMan® Genotyping Master Mix and assays for CYP2B6 ‐516G > T (rs3745274, C_7817765_60), CYP2B6 ‐983T > C (rs28399499, C_60732328_20), CYP2B6 ‐c.485‐18C > T (rs4803419; C_7817764_10), CYP2B6 ‐499C > G (rs3826711, C__27522377_10; ARROW patients only), CYP3A4 *22 (rs35599367, C__59013445_10), CYP3A5 ‐6986G > A (rs776746, C__59013445_10), NR1I3 (rs3003596, C__16194070_10; rs2307424, C__25746794_20), NR1I2 ‐63396C > T (rs2472677, C__26079845_10) were obtained from Life Technologies Ltd (Paisley, Renfrewshire, UK).

    Article Title:
    Article Snippet: Pre-designed TaqMan assays (Applied Biosystems, Foster City, CA, USA) were used to genotype CYP2B6 g.3003T > C (assay ID C_2818167_10), c.516G > T (assay ID C_7817765_60), g.18492T > C (assay ID C_26823975_10) and g.21563C > T (assay ID C_22275631_10) and ABCB1 c.3435C > T (assay ID C_7586657_20).

    Article Title:
    Article Snippet: SNPs were analyzed using the validated Taqman Genotyping Assays purchased from Applied Biosystems for CYP2B6 516G > T (rs3745274; assay ID C_7817765_60) and CYP2B6 983T > C (rs28399499; assay ID C_60732328_20), according to the manufacturer’s instructions.

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97
    Thermo Fisher snp cyp2b6 c 7817765 60
    Nevirapine plasma concentrations following a 200 mg dose to A) African Americans and B) European Americans. The concentrations (mean ± SEM) are stratified by <t>CYP2B6</t> 516G > T genotype: circles GG, squares GT and triangles TT.
    Snp Cyp2b6 C 7817765 60, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 97/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/snp cyp2b6 c 7817765 60/product/Thermo Fisher
    Average 97 stars, based on 10 article reviews
    Price from $9.99 to $1999.99
    snp cyp2b6 c 7817765 60 - by Bioz Stars, 2020-08
    97/100 stars
      Buy from Supplier

    Image Search Results


    Nevirapine plasma concentrations following a 200 mg dose to A) African Americans and B) European Americans. The concentrations (mean ± SEM) are stratified by CYP2B6 516G > T genotype: circles GG, squares GT and triangles TT.

    Journal: Pharmacogenetics and genomics

    Article Title: Measuring the Overall Genetic Component of Nevirapine Pharmacokinetics and the Role of Selected Polymorphisms: Towards Addressing the Missing Heritability in Pharmacogenetic Phenotypes?

    doi: 10.1097/FPC.0b013e32836533a5

    Figure Lengend Snippet: Nevirapine plasma concentrations following a 200 mg dose to A) African Americans and B) European Americans. The concentrations (mean ± SEM) are stratified by CYP2B6 516G > T genotype: circles GG, squares GT and triangles TT.

    Article Snippet: TaqMan assays were used to genotype CYP2B6 516G > T (rs3745274, Assay ID: C___7817765_60) and ABCB1 3435C > T (rs1045642, Assay ID: C___7586657_20).

    Techniques:

    Study flow diagram. Abbreviations: ART, antiretroviral therapy; CYP2B6 , cytochrome P450 2B6 .

    Journal: Pharmacogenomics and Personalized Medicine

    Article Title: A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study

    doi: 10.2147/PGPM.S86446

    Figure Lengend Snippet: Study flow diagram. Abbreviations: ART, antiretroviral therapy; CYP2B6 , cytochrome P450 2B6 .

    Article Snippet: Predesigned TaqMan assays (Applied Biosystems, Foster City, CA, USA) were used to genotype the predesigned TaqMan assays (Applied Biosystems) and were also used to genotype the CYP2B6 c.516G > T (assay ID C__7817765_60), c.64C > T (assay ID C__2818162_20), c.499C > G (assay ID C__2752377_10), c.1375A > G (assay ID C__2741754_10), c.1459C > T (assay ID C__30634242_40), g.3003T > C (assay ID C__2818167_10), and g.21563C > T (assay ID C__22275631_10).

    Techniques: Flow Cytometry

    Efavirenz concentrations in plasma at 4, 12, and 24 weeks. Note: The boxes represent interquartile range and lines represent minimum and maximum value. Abbreviation: CYP2B6 , cytochrome P450 2B6 .

    Journal: Pharmacogenomics and Personalized Medicine

    Article Title: A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study

    doi: 10.2147/PGPM.S86446

    Figure Lengend Snippet: Efavirenz concentrations in plasma at 4, 12, and 24 weeks. Note: The boxes represent interquartile range and lines represent minimum and maximum value. Abbreviation: CYP2B6 , cytochrome P450 2B6 .

    Article Snippet: Predesigned TaqMan assays (Applied Biosystems, Foster City, CA, USA) were used to genotype the predesigned TaqMan assays (Applied Biosystems) and were also used to genotype the CYP2B6 c.516G > T (assay ID C__7817765_60), c.64C > T (assay ID C__2818162_20), c.499C > G (assay ID C__2752377_10), c.1375A > G (assay ID C__2741754_10), c.1459C > T (assay ID C__30634242_40), g.3003T > C (assay ID C__2818167_10), and g.21563C > T (assay ID C__22275631_10).

    Techniques:

    Linkage disequilibrium (LD) plot of CYP2B6 polymorphisms. Data from all 34 participants are included. Black, r 2 = 1; shades of grey 0

    Journal: The Journal of infectious diseases

    Article Title: Relationships between CYP2B6 Polymorphisms and Pharmacokinetics Following a Single Dose of Nevirapine or Efavirenz in African Americans

    doi: 10.1086/597125

    Figure Lengend Snippet: Linkage disequilibrium (LD) plot of CYP2B6 polymorphisms. Data from all 34 participants are included. Black, r 2 = 1; shades of grey 0

    Article Snippet: TaqMan™ assays were used to genotype CYP2B6 polymorphisms 516G > T (rs3745274, assay ID C_7817765_60) and 983T > C (rs28399499, assay ID C_60732328_10).

    Techniques:

    Plasma concentration-time curves for nevirapine and efavirenz. Each curve represents a different study participant. A pre-dose concentration of zero was assigned to all participants. Individuals with a composite CYP2B6 516/983 slow metabolizer genotype

    Journal: The Journal of infectious diseases

    Article Title: Relationships between CYP2B6 Polymorphisms and Pharmacokinetics Following a Single Dose of Nevirapine or Efavirenz in African Americans

    doi: 10.1086/597125

    Figure Lengend Snippet: Plasma concentration-time curves for nevirapine and efavirenz. Each curve represents a different study participant. A pre-dose concentration of zero was assigned to all participants. Individuals with a composite CYP2B6 516/983 slow metabolizer genotype

    Article Snippet: TaqMan™ assays were used to genotype CYP2B6 polymorphisms 516G > T (rs3745274, assay ID C_7817765_60) and 983T > C (rs28399499, assay ID C_60732328_10).

    Techniques: Concentration Assay

    Impact of CYP2B6 polymorphisms; 516G > T (A), 785A > G (B), 18492T > C (C) and 21563C > T (1D) on efavirenz (EFV) plasma concentrations. Middle bar indicates the median and grey bar indicates the interquartile range. Mann–Whitney tests were used to compare efavirenz concentrations between two genotypes

    Journal: British Journal of Clinical Pharmacology

    Article Title: Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults

    doi: 10.1111/j.1365-2125.2012.04288.x

    Figure Lengend Snippet: Impact of CYP2B6 polymorphisms; 516G > T (A), 785A > G (B), 18492T > C (C) and 21563C > T (1D) on efavirenz (EFV) plasma concentrations. Middle bar indicates the median and grey bar indicates the interquartile range. Mann–Whitney tests were used to compare efavirenz concentrations between two genotypes

    Article Snippet: Pre-designed TaqMan assays (Applied Biosystems, Foster City, CA) were used to genotype the CYP2B6 g.3003T > C (assay ID C__2818167_10), c.516G > T (assay ID C__7817765_60), g.18492C > T (assay ID C__26823975_10), g.21563C > T (assay ID C__22275631_10), c.64C > T (assay ID C__2818162_20), c.499C > G (assay ID C__2752377_10), c.1375A > G (assay ID C__2741754_10) and c.1459C > T (assay ID C__30634242_40).

    Techniques: MANN-WHITNEY

    Linkage disequilibrium of CYP2B6 for each polymorphism, data represents six SNPs in Haploview 4.2 software. Red quadrate without D' worth display mean D' = 1, LOD ≥2 while pale blue square mean D' = 1, LOD

    Journal: British Journal of Clinical Pharmacology

    Article Title: Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults

    doi: 10.1111/j.1365-2125.2012.04288.x

    Figure Lengend Snippet: Linkage disequilibrium of CYP2B6 for each polymorphism, data represents six SNPs in Haploview 4.2 software. Red quadrate without D' worth display mean D' = 1, LOD ≥2 while pale blue square mean D' = 1, LOD

    Article Snippet: Pre-designed TaqMan assays (Applied Biosystems, Foster City, CA) were used to genotype the CYP2B6 g.3003T > C (assay ID C__2818167_10), c.516G > T (assay ID C__7817765_60), g.18492C > T (assay ID C__26823975_10), g.21563C > T (assay ID C__22275631_10), c.64C > T (assay ID C__2818162_20), c.499C > G (assay ID C__2752377_10), c.1375A > G (assay ID C__2741754_10) and c.1459C > T (assay ID C__30634242_40).

    Techniques: Software

    CYP2B6 GAC haplotype. Middle bar indicates the median and grey box indicates the interquartile range. Asterisks represent an individual subject

    Journal: British Journal of Clinical Pharmacology

    Article Title: Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults

    doi: 10.1111/j.1365-2125.2012.04288.x

    Figure Lengend Snippet: CYP2B6 GAC haplotype. Middle bar indicates the median and grey box indicates the interquartile range. Asterisks represent an individual subject

    Article Snippet: Pre-designed TaqMan assays (Applied Biosystems, Foster City, CA) were used to genotype the CYP2B6 g.3003T > C (assay ID C__2818167_10), c.516G > T (assay ID C__7817765_60), g.18492C > T (assay ID C__26823975_10), g.21563C > T (assay ID C__22275631_10), c.64C > T (assay ID C__2818162_20), c.499C > G (assay ID C__2752377_10), c.1375A > G (assay ID C__2741754_10) and c.1459C > T (assay ID C__30634242_40).

    Techniques: